[go: up one dir, main page]

CO5011053A1 - Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento - Google Patents

Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento

Info

Publication number
CO5011053A1
CO5011053A1 CO99074400A CO99074400A CO5011053A1 CO 5011053 A1 CO5011053 A1 CO 5011053A1 CO 99074400 A CO99074400 A CO 99074400A CO 99074400 A CO99074400 A CO 99074400A CO 5011053 A1 CO5011053 A1 CO 5011053A1
Authority
CO
Colombia
Prior art keywords
procedure
hydroclorotiazida
production
dosage form
solid dosage
Prior art date
Application number
CO99074400A
Other languages
English (en)
Inventor
Rudolf Heller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5011053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5011053A1 publication Critical patent/CO5011053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación de una combinación farmacéutica quecontiene las substancias activas carvedilol o una sal farmacéuticamente aceptable de la misma e hidroclorotiazida o una sal farmacéuticamente aceptable de la misma, así como aditivos usuales farmacéuticamente.
CO99074400A 1998-11-27 1999-11-25 Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento CO5011053A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27

Publications (1)

Publication Number Publication Date
CO5011053A1 true CO5011053A1 (es) 2001-02-28

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99074400A CO5011053A1 (es) 1998-11-27 1999-11-25 Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento

Country Status (22)

Country Link
US (3) US6403579B1 (es)
EP (1) EP1131072B1 (es)
JP (2) JP2002531395A (es)
KR (1) KR100421347B1 (es)
CN (1) CN1184971C (es)
AR (1) AR020287A1 (es)
AT (1) ATE238056T1 (es)
AU (1) AU765977B2 (es)
BR (1) BR9915610A (es)
CA (1) CA2352361C (es)
CO (1) CO5011053A1 (es)
DE (1) DE69907252T2 (es)
DK (1) DK1131072T3 (es)
ES (1) ES2195638T3 (es)
MY (1) MY121831A (es)
PE (1) PE20001302A1 (es)
PT (1) PT1131072E (es)
TR (3) TR200200981T2 (es)
TW (1) TWI228414B (es)
UY (1) UY25821A1 (es)
WO (1) WO2000032174A2 (es)
ZA (1) ZA200104280B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (es) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
CN1678305A (zh) 2002-06-27 2005-10-05 Sb药物波多黎各公司 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
JP2005533822A (ja) 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
EP1615888A1 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
WO2005030201A1 (en) * 2003-09-26 2005-04-07 Shuyi Zhang Sustained release preparation containing hydrochlorothiazide
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
ATE358478T1 (de) * 2003-12-02 2007-04-15 Nicox Sa Nitrooxy-derivate von carvedilol und anderen betablockern als antihypertensiva
WO2006089674A2 (en) * 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
CA2792647A1 (en) * 2010-03-10 2011-09-15 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
CZ286723B6 (cs) * 1991-01-30 2000-06-14 The Wellcome Foundation Limited Tablety dispergovatelné ve vodě
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida

Also Published As

Publication number Publication date
UY25821A1 (es) 2001-07-31
TR200200981T2 (tr) 2002-06-21
US6403579B1 (en) 2002-06-11
JP2007077160A (ja) 2007-03-29
DE69907252T2 (de) 2004-01-29
ES2195638T3 (es) 2003-12-01
EP1131072B1 (en) 2003-04-23
US20040087578A1 (en) 2004-05-06
BR9915610A (pt) 2001-08-14
DE69907252D1 (de) 2003-05-28
JP2002531395A (ja) 2002-09-24
TR200101470T2 (tr) 2001-11-21
EP1131072A2 (en) 2001-09-12
AU765977B2 (en) 2003-10-09
PT1131072E (pt) 2003-08-29
ZA200104280B (en) 2002-08-26
WO2000032174A3 (en) 2000-11-16
KR100421347B1 (ko) 2004-03-06
TWI228414B (en) 2005-03-01
ATE238056T1 (de) 2003-05-15
US20020052367A1 (en) 2002-05-02
CN1184971C (zh) 2005-01-19
MY121831A (en) 2006-02-28
AR020287A1 (es) 2002-05-02
CA2352361C (en) 2007-01-02
AU1506500A (en) 2000-06-19
TR200200982T2 (tr) 2002-06-21
PE20001302A1 (es) 2000-11-30
CN1328460A (zh) 2001-12-26
WO2000032174A2 (en) 2000-06-08
CA2352361A1 (en) 2000-06-08
KR20010080578A (ko) 2001-08-22
DK1131072T3 (da) 2003-08-11

Similar Documents

Publication Publication Date Title
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
AR032293A1 (es) Estuche farmaceutico
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
PA8591701A1 (es) Derivados de pirrolopirimidina
EA200501586A1 (ru) Фармацевтические продукты
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
CO5190688A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma de compuesto formado in situ con una hidrosolubilidad 100 mg/ml, y procedimientos para su preparac
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
ES2178896T3 (es) Nueva forma de sal de pantoprazol.
DE50105771D1 (de) Ibuprofen-wirkstoffzubereitung
CR9363A (es) Composiciones para la transmision transmucosa oral de la metformina
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
AR042308A1 (es) Medicamento de administracion transdermica y transmucosica con absorcion mejorada de principios activos
SE0000303D0 (sv) Novel compounds
AR023788A1 (es) Modificacion amorfa de torasemida